ArticleNature communications2022
Artificially sporulated Escherichia coli cells as a robust cell factory for interfacial biocatalysis.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 59 citations in OpenAlex.
- Pollen-Based Artificial Enzyme With Efficient Biocatalysis and Immune-Priming to Prevent Primary and Secondary Wound Infection.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- A Cholesterol Analogue for Cell-Surface Enzyme Display.Angewandte Chemie (International ed. in English) · 2026Article
- Assembly-Line Biosynthesis in Living-Cell Emulsions via Tunable Supramolecular Surface Chemistry.Nature communications · 2026Article
- Ambient synthesis of single-atom catalysts on catalytically active cells for chemoenzymatic cascades.Nature communications · 2026Article
- Concurrent Linear Deracemization of Secondary Benzylic Alcohols via Simultaneous Photocatalysis and Whole-cell Biocatalysis.ACS catalysis · 2025Article
- Pickering Emulsion Biocatalysis with Engineered Living Cells for Degrading Polycarbonate Plastics.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Autonomous chemo-metabolic construction of anisotropic cell-in-shell nanobiohybrids in enzyme-powered cell microrobots.Science advances · 2025Article
- Pickering emulsions with low interface coverage but enhanced stability for emulsion interface catalysis and SERS-based detection.Nature communications · 2025Article
- Protein-cell conjugates as artificial surface display for interfacial biocatalysis.Chemical science · 2025Article
- Co-immobilization of whole cells and enzymes by covalent organic framework for biocatalysis process intensification.Nature communications · 2024Article
- Biocatalytic Synthesis Using Self-Assembled Polymeric Nano- and Microreactors.Angewandte Chemie (International ed. in English) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The natural bacterial spores have inspired the development of artificial spores, through coating cells with protective materials, for durable whole-cell catalysis. Despite attractiveness, artificial spores developed to date are generally limited to a few microorganisms with their natural endogenous enzymes, and they have never been explored as a generic platform for widespread synthesis. Here, we report a general approach to designing artificial spores based on Escherichia coli cells with recombinant enzymes. The artificial spores are simply prepared by coating cells with polydopamine, which can withstand UV radiation, heating and organic solvents. Additionally, the protective coating enables living cells to stabilize aqueous-organic emulsions for efficient interfacial biocatalysis ranging from single reactions to multienzyme cascades. Furthermore, the interfacial system can be easily expanded to chemoenzymatic synthesis by combining artificial spores with metal catalysts. Therefore, this artificial-spore-based platform technology is envisioned to lay the foundation for next-generation cell factory engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.